Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTBP2 | P56545 | 1/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 4/20 | 0.43 |
| ▸ | DRD3 | P35462 | 3/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.43 |
| ▸ | DRD1 | P21728 | 2/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | DRD5 | P21918 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5174907 | 1.00 | CTBP2 (0.45) | CTBP2ENPP2DRD2DRD3OPRK1 | |
| SCHEMBL27647339 | 1.00 | CTBP2 (0.45) | CTBP2ENPP2DRD2DRD3OPRK1 | |
| SCHEMBL29053361 | 0.84 | CTBP2 (0.46) | CTBP2ENPP2DRD2DRD3OPRK1 | |
| SCHEMBL2165273 | 0.83 | CTBP2 (0.47) | CTBP2IDO1GRM2GRM3TAAR1 | |
| SCHEMBL2165272 | 0.83 | CTBP2 (0.47) | CTBP2IDO1GRM2GRM3TAAR1 | |
| SCHEMBL586073 | 0.81 | BLM (0.65) | CTBP2ENPP2DRD2DRD3OPRK1 | |
| SCHEMBL586074 | 0.81 | BLM (0.65) | CTBP2ENPP2DRD2DRD3OPRK1 | |
| SCHEMBL1275761 | 0.81 | SMN1; SMN2 (0.55) | TAAR1BLMCYP1A2CYP3A4ALDH1A1 | |
| SCHEMBL3361395 | 0.81 | SMN1; SMN2 (0.55) | TAAR1BLMCYP1A2CYP3A4ALDH1A1 | |
| SCHEMBL180161 | 0.81 | SMN1; SMN2 (0.55) | TAAR1BLMCYP1A2CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807692-B2 | Antidiabetic oxazolidinediones and thiazolidinediones | MERCK SHARP & DOHME CORP. (US) | 2010-10-05 | — | — | US | disclosed |
| US-20100168164-A1 | Antidiabetic Oxazolidinediones and Thiazolidinediones | MERCK SHARP & DOHME CORP. | 2010-07-01 | — | — | US | disclosed |
| US-20090069385-A1 | Antidiabetic Oxazolidinediones and Thiazolidinediones | MERCK SHARP & DOHME CORP. | 2009-03-12 | — | — | US | disclosed |
| CN-100451008-C | Antidiabetic oxazolidinediones and thiazolidinediones | MERCK & CO INC (US) | 2009-01-14 | — | — | CN | disclosed |
| EP-1909789-A2 | ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES | Merck & Co., Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| US-20070173434-A1 | Antidiabetic oxazolidinediones and thiazolidinediones | MERCK SHARP & DOHME CORP. | 2007-07-26 | — | — | US | disclosed |
| EP-1709014-B1 | ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES | MERCK & CO INC (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2007018956-A2 | ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES | MERCK & CO., INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| CN-1910163-A | Antidiabetic oxazolidinediones and thiazolidinediones | MERCK & CO INC (US) | 2007-02-07 | — | — | CN | disclosed |
| EP-1709014-A1 | ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES | Merck & Co., Inc. (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005070905-A1 | ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES | MERCK & CO., INC. (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069385-A1 | Antidiabetic Oxazolidinediones and Thiazolidinediones | PPARD, PPARA, PPARG | CTBP2 1712/4885ENPP2 2212/4885DRD2 291/4885 |
| US-20100168164-A1 | Antidiabetic Oxazolidinediones and Thiazolidinediones | PPARD, PPARA, PPARG | CTBP2 1475/4885ENPP2 2231/4885DRD2 298/4885 |
| US-20070173434-A1 | Antidiabetic oxazolidinediones and thiazolidinediones | PPARD, PPARA, PPARG | CTBP2 2520/4885ENPP2 2931/4885DRD2 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.